论文部分内容阅读
目的:观察膈下逐瘀汤联合西药治疗乙型肝炎肝硬化代偿期患者的临床效果。方法:将95例乙型肝炎肝硬化代偿期气滞血瘀证患者随机分为治疗组50例和对照组45例,对照组给予常规西药抗病毒治疗,治疗组在对照组基础上加服膈下逐瘀汤治疗。治疗前后检测和比较2组肝功能指标[总胆红素(TBil)、白蛋白(Alb)、谷丙转氨酶(ALT)]、免疫功能指标[CD3~+、CD4~+、自然杀伤(NK)细胞活性]及肝纤维化指标[透明质酸酶(HA)、层粘连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原(PCⅢ)],并评估2组治疗期间的用药安全性。结果:治疗后,2组TBil、Alb、ALT及HA、LN、Ⅳ-C、PCⅢ水平均较治疗前降低(P<0.05),CD3~+、CD4~+、NK细胞活性均较治疗前上升(P<0.05),治疗组10项指标的改善均优于对照组(P<0.05)。2组患者在治疗期间均未见明显过敏反应及其他不良反应。结论:采用膈下逐瘀汤联合西药治疗乙型肝炎肝硬化代偿期,可改善患者的肝功能,增强患者的免疫力,并可发挥显著的抗肝纤维化作用,从而预防血液高凝状态。
Objective: To observe the clinical effect of Gexia Zhuyu Decoction combined with Western medicine in the treatment of hepatitis B cirrhosis patients. Methods: A total of 95 patients with hepatitis B cirrhosis with compensatory qi stagnation and blood stasis syndrome were randomly divided into treatment group (n = 50) and control group (n = 45). The control group was given routine western antiviral therapy. The treatment group Diabetes Zhuyu decoction treatment. Before and after treatment, the indexes of liver function (TBil, Alb, ALT), indexes of immune function [CD3 ~ +, CD4 ~ + and natural killer (NK) Cell activity] and indicators of liver fibrosis [hyaluronidase (HA), laminin (LN), type Ⅳ collagen (Ⅳ-C), type Ⅲ procollagen (PC Ⅲ)] safety. Results: After treatment, the levels of TBil, Alb, ALT, HA, LN, Ⅳ-C and PCⅢ in the two groups were significantly lower than those before treatment (P < (P <0.05). The improvement of 10 indexes in the treatment group was better than that in the control group (P <0.05). No significant allergic reactions and other adverse reactions were observed in the two groups during treatment. Conclusion: The treatment of decompensated hepatitis B cirrhosis with Gexia Zhuyu decoction combined with Western medicine can improve the liver function of patients, enhance the immunity of patients and exert significant anti-hepatic fibrosis, thus preventing hypercoagulable state of blood .